Annexin A1-derived peptide Ac2-26 in a pilocarpine-induced status epilepticus model: anti-inflammatory and neuroprotective effects

Alexandre D. Gimenes1, Bruna F. D. Andrade2, José Victor P. Pinotti1, Sonia M. Oliani1,3, Orfa Y. Galvis-Alonso2† and Cristiane D. Gil1,3*†

Abstract

Background: The inflammatory process has been described as a crucial mechanism in the pathophysiology of temporal lobe epilepsy. The anti-inflammatory protein annexin A1 (ANXA1) represents an interesting target in the regulation of neuroinflammation through the inhibition of leukocyte transmigration and the release of proinflammatory mediators. In this study, the role of the ANXA1-derived peptide Ac2-26 in an experimental model of status epilepticus (SE) was evaluated.

Methods: Male Wistar rats were divided into Naive, Sham, SE and SE+Ac2-26 groups, and SE was induced by intrahippocampal injection of pilocarpine. In Sham animals, saline was applied into the hippocampus, and Naive rats were only handled. Three doses of Ac2-26 (1 mg/kg) were administered intraperitoneally (i.p.) after 2, 8 and 14 h of SE induction. Finally, 24 h after the experiment-onset, rats were euthanized for analyses of neuronal lesion and inflammation.

Results: Pilocarpine induced generalised SE in all animals, causing neuronal damage, and systemic treatment with Ac2-26 decreased neuronal degeneration and albumin levels in the hippocampus. Also, both SE groups showed an intense influx of microglia, which was corroborated by high levels of ionised calcium binding adaptor molecule 1 (Iba-1) and monocyte chemoattractant protein-1 (MCP-1) in the hippocampus. Ac2-26 reduced the astrocyte marker (glial fibrillary acidic protein; GFAP) levels, as well as interleukin-1β (IL-1β), interleukin-6 (IL-6) and growth-regulated alpha protein (GRO/KC). These effects of the peptide were associated with the modulation of the levels of formyl peptide receptor 2, a G-protein-coupled receptor that binds to Ac2-26, and the phosphorylated extracellular signal-regulated kinase (ERK) in the hippocampal neurons.

Conclusions: These data suggest a neuroprotective effect of Ac2-26 in the epileptogenic processes through downregulation of inflammatory mediators and neuronal loss.

Keywords: Cytokines, ERK, Fpr2, Glia, Hippocampus, Neuroinflammation

* Correspondence: cristiane.gil@unifesp.br
† Orfa Y. Galvis-Alonso and Cristiane D. Gil contributed equally to this work.
1Department of Morphology and Genetics, Federal University of São Paulo (UNIFESP), São Paulo, SP 04023-900, Brazil
3From the Post-Graduation in Biosciences, Instituto de Biociências, Letras e Ciências Exatas, São Paulo State University (IBILCE/UNESP), São José do Rio Preto, SP 15054-000, Brazil
Full list of author information is available at the end of the article

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Epilepsy is a brain disease characterised by an enduring predisposition to generate epileptic seizures and by the neurobiological, cognitive, psychological and social consequences of this condition [1]. Temporal lobe epilepsy (TLE) is a type of focal epilepsy that has a great clinical relevance due to its high incidence and severity, and the commonest pathology underlying the TLE is unilateral hippocampal sclerosis associated with neuronal loss and gliosis [2]. These characteristics can be reproduced in animals using pilocarpine, a muscarinic receptor agonist [3]. In this model, the systemic or intracerebral application of pilocarpine induces the following steps: (1) an acute period that progressively develops in 24-h limbic status epilepticus (SE); (2) a silent period with progressive normalisation of behaviour and electroencephalogram, which varies from 4 to 44 days, and (3) a chronic period with recurrent spontaneous seizures [4, 5]. In addition, neuronal death and gliosis occur in the hippocampus and extrahippocampal regions, and the subsequent development of recurrent spontaneous seizures is similar to the development observed in complex partial seizures in humans [6–9].

Clinical and experimental evidence support the hypothesis that the inflammatory process in the brain is a common and crucial mechanism of epileptic seizures and epilepsy [10, 11]. The first evidence of the role of inflammation in human epilepsy was obtained clinically, showing that steroids and other anti-inflammatory drugs have anti-convulsant activity in patients refractory to conventional therapy [12]. Furthermore, increased serum levels of interleukins interleukin-1β (IL-1β), interleukin-6 (IL-6) and IL-1 receptor antagonists were detected in patients with epilepsy [13]. In nervous tissue, astrocytes and microglia are important sources of proinflammatory cytokines, such as IL-1β, IL-6 and TNF-α, and contribute to the epileptogenic process [10, 11]. However, the molecular mechanisms by which inflammation can increase the excitability of neurons are still unclear and open new perspectives for the treatment or prevention of these neurological diseases.

This scenario highlights annexin A1 (ANXA1), a 37 kDa protein that mimics the action of glucocorticoids by inhibiting the synthesis of eicosanoids and phospholipase A₂, the leukocyte migration and the release of proinflammatory cytokines, thus contributing to the control of the inflammatory response [14]. In addition, increased levels of ANXA1 in the human brain, as well as in the activated glia (microglia and astrocytes) or scar tissue, have been described in different neurological pathologies, suggesting a role of this protein in response to neural injury [15]. Similarly, kainic acid-lesioned rat cerebellum presented increased levels of ANXA1 in the activated microglia at 24 h and later in the astrocytes (5 days) [16]. The neuroprotective role of ANXA1 was also demonstrated in a rat stroke model where administering the ANXA1 mimetic peptide (Ac₂-26) decreased the size of the lesion and limited neutrophil infiltration [17, 18]. In addition, administering the recombinant human ANXA1 also could attenuate beta-amyloid-induced blood-brain barrier (BBB) impairment in vitro, suppressing microglial activation and clearing apoptotic neurons [19].

The biological actions of ANXA1 and its derived peptides can occur through functional interaction with formyl peptide receptors (Fpr), a family of G-protein-coupled receptors, and especially formyl peptide receptor 2 (Fpr2) [20, 21]. After binding to their agonists, these receptors activate a variety of signalling pathways, including intracellular calcium influx and activation of mitogen-activated protein kinases (MAPKs) which are important regulators of synaptic excitability and cognitive impairment in epilepsy [22]. These data reveal ANXA1 plays a significant role in the central nervous system diseases which, although of varying and often indefinite aetiology, share a common neuroinflammatory component. Thus, this study evaluates the role of pharmacological treatment with ANXA1-derived peptide Ac₂-26 in the pilocarpine-induced status epilepticus (SE) in rats.

Methods
Animals
Adult male Wistar rats (200–250 g) were housed in a 12-h light-dark cycle with a controlled temperature (22 ± 2 °C) and relative humidity air between 40% and 60% and were allowed food and water ad libitum. Furthermore, the animals were carefully handled for 7 days prior to the initiation of the experiments for stress reduction. All procedures were approved by the Ethics Committee in Animal Experimentation of the Federal University of São Paulo - UNIFESP (CEUA No. 295805081) and agreed with the guidelines established by the National Council for the Control of Animal Experimentation (CONCEA).

Induction of SE and pharmacological treatments
Rats were distributed into the following four groups: Naive (n = 12), Sham (n = 12), SE (n = 14) and SE+Ac₂-26 (treated with the mimetic peptide of ANXA1; n = 12). Stereotoxic surgery was performed in animals from the Sham, SE and SE+Ac₂-26 groups. They were then anesthetized with aecpromazine-ketamine-xylazine (1 mg/kg subcutaneously and 50 and 10 mg/kg intramuscularly, respectively) and received 1 ml/kg of veterinary pentabiotic (Fort Dodge, Campinas, SP, Brazil) to avoid infection. Cannula was implanted in the right posterior dorsal hippocampus with the following stereotaxic coordinates: AP − 5.9 mm, ML − 4.3 mm, and DV 3.5 mm [20].
Seven days after surgery, SE was induced according to previous studies [23, 24]. SE and SE+Ac$_{2-26}$ groups received an intrahippocampal injection of pilocarpine (0.9 mg/animal; Sigma-Aldrich Corporation, St. Louis, MO, USA, Cat No. P6503-10G) diluted in 1 μl of sterile saline, while Sham received only 0.9% saline (1 μl). Also, ANXA1-derived peptide Ac$_{2-26}$ (Ac-AMVSEFLKQAWFIENEEQYQTVK; Invitrogen, São Paulo, Brazil) was diluted in sterile saline and administered at 1 mg/kg intraperitoneally (i.p.) [25, 26], after 2, 8 and 14 h of SE induction. Doses of Ac$_{2-26}$ were scaled up from the pilot study. In parallel, Sham and SE rats received 0.9% saline i.p., while Naïve animals were only handled.

Each animal was placed in an individual acrylic box for behavioural assessment according to the Racine’s scale [27], for a period of 4 h after the onset of SE. SE was defined as continuous stage three or greater seizures and, for each rat, the SE type was labelled considering the predominant seizure type displayed for at least 2 h.

All animals received diazepam (DZP, 10 mg/kg; i.p.) 4 h after SE establishment. Naïve and Sham groups were also injected with DZP in the same conditions, and animals submitted to SE were kept hydrated by subcutaneous injection of saline every 3 h. Then, 24 h after the pilocarpine injection, animals were euthanized by overdosage of sodium thiopental and the brains were collected.

Analysis of neuronal degeneration
The animals were perfused via a cannula into the left ventricle of the heart with 0.9% saline followed by 4% phosphate-buffered paraformaldehyde. After perfusion, the brains were removed and fixed for an additional 4 h, subsequently dehydrated in ethanol 50% to 100% and xylene, and then embedded in paraffin. Brain coronal sections of 8 μm were obtained in a Leica RM2155 microtome (Leica Microsystems, Nussloch, Germany) and subsequently stained with haematoxylin-eosin (H&E) or Fluoro-Jade C (FJC) [28] for quantification of normal and degenerating neurons, respectively.

Analysis of microglia and astrocytes in the hippocampus
For the localization of microglia and astrocytes in the hippocampus, immunohistochemistry according to the Racine’s scale [27], for a period of 4 h after the onset of SE. SE was defined as continuous stage three or greater seizures and, for each rat, the SE type was labelled considering the predominant seizure type displayed for at least 2 h.

All animals received diazepam (DZP, 10 mg/kg; i.p.) 4 h after SE establishment. Naïve and Sham groups were also injected with DZP in the same conditions, and animals submitted to SE were kept hydrated by subcutaneous injection of saline every 3 h. Then, 24 h after the pilocarpine injection, animals were euthanized by overdosage of sodium thiopental and the brains were collected.

Expression of Fpr2 and extracellular signal-regulated kinase (ERK) in the hippocampus
The analyses of Fpr2 and ERK expression in the hippocampus were performed using immunohistochemistry [26]. After an antigen retrieval step using citrate buffer (pH 6.0) at 96°C for 30 min, endogenous peroxide activity was blocked, and the hippocampal sections were incubated overnight at 4°C with the primary rabbit polyclonal antibody anti-Fpr2 (1:2000; Santa Cruz Biotechnology, CA, USA, Cat No. sc-57141) and mouse monoclonal anti-phosphorylated (p)ERK ½ (1:1000, Cell Signaling, Danvers, MA, EUA, Cat No. mAb #4370) diluted in 1% BSA. After washing, the sections were incubated with a secondary biotinylated antibody (LAB-SA Detection kit, Invitrogen, Paisley, UK, Cat No. 95-9843). Positive staining was then detected using a peroxidase-conjugated streptavidin complex, and colour was developed using 3,3′-Diaminobenzidine (DAB) substrate (Dako, Cambridge, UK, Cat No. K3468). Lastly, the sections were counterstained with haematoxylin.
Analysis of cytokine and chemokine levels
Hippocampal samples were sonicated in a 50 mM Tris-HCl, 150 mM NaCl and 1% Triton-X pH 7.4 buffer containing a complete protease inhibitor cocktail and PhosSTOP tablets (Roche Applied Science, Mannheim, Germany, Cat No. 04906537001). Subsequently, samples were centrifuged at 10,000 × g for 20 min at 4 °C to obtain organ homogenates. For multiplex analysis, 25 μl of the hippocampal homogenates were employed using the MILLIPLEX MAP rat cytokine/chemokine panel (MILLIPLEX MAP RECYTMAG-65 K, Millipore Corporation, EUA, Cat No. #RECYMAG65K27PMX) and MAGPIX® Multiplexing Instrument (Millipore) according to the manufacturer’s instructions. Five analytes were studied in this work: IL-1β, IL-6, TNF-α (tumour necrosis factor-α), GRO/KC (growth-regulated alpha protein; also known as CXCL1) and MCP-1 (monocyte chemoattractant protein-1). The concentration of analytes was determined by MAGPIX Xponent software (Millipore Corporation, Billerica, MA, USA), and the results are reported as the mean ± SEM.

Western blotting analysis
Protein levels of hippocampal homogenates were determined by Bradford assay and normalised prior to boiling in the Laemmli buffer (Bio-Rad Laboratories, USA, Cat No. #1610737). Pooled protein extracts (30 μg per lane) of hippocampus (n = 3 animals per group) from the indicated experimental conditions were loaded onto a 12% sodium dodecyl sulphate-polyacrylamide gel for electrophoresis together with appropriate molecular weight markers (Bio-Rad Life Science, USA, Cat No. 4110182) and transferred to ECL Hybond nitrocellulose membranes. Also, reversible protein staining of the membranes with 0.1% Ponceau-S in 5% acetic acid (Santa Cruz Biotechnology, CA, USA, Cat No. CAS 6226-79-5) was used to verify protein transfer. In this process, the membranes were incubated for 15 min in 5% BSA in Tris-buffered saline (TBS) prior to incubation with antibodies, and the primary antibodies used in this work were rabbit polyclonal anti-albumin (1:2000, Abcam, Cambridge, MA, USA, Cat No. ab10658), anti-Iba1 and anti-GFAP (1:500; Novus Biological, Littleton, CO, USA, Cat No. NBP2-16908 and NB300-141), anti-ANXA1 and anti-Fpr2 (1:200; Santa Cruz Biotechnology, CA, USA, Cat No. sc-12740 and sc-57141), anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH;1:5000; Sigma-Aldrich, St. Louis, Missouri, USA, Cat No. G9545-100UL), anti-ERK and mouse monoclonal anti-phosphorylated ERK1/2 (1:2000; Cell Signalling, Danvers, MA, EUA, Cat No. mAb #9102 and #4370), which all the antibodies were diluted in TBS with 0.1% Tween 20. For post-incubation with primary antibodies, membranes were washed for 15 min with TBS and subsequently incubated for 60 min at room temperature with the appropriate secondary antibodies. The secondary antibodies were peroxidase-conjugated rabbit anti-goat IgG, goat anti-rabbit (1:2000, Thermo Fisher Scientific Inc., MI, USA, Cat No. #31402 and #31460) or goat anti-mouse (1:2000, Millipore Corporation, CA USA, Cat No. 12-349). Finally, membranes were washed for 15 min with TBS, and immunoreactive proteins were detected (Westar Nova 2.0 chemiluminescent substrate kit; Cyanagen, Bologna, Italy, Cat No. XLS071,0250) using a GeneGnome® chemiluminescence detection system (SynGene, Cambridge, UK). Proteins were then imaged and quantified using GeneTools software (SynGene) to determine the relative expression of indicated proteins (arbitrary units, a.u.).

Statistical analysis
GraphPad software version 6.00 (GraphPad Software, La Jolla, CA, USA) was used for the statistical analysis, and normality was determined by performing the Kolmogorov-Smirnov test. In samples with a normal distribution, the analysis of variance (ANOVA) was applied and then the Bonferroni post-test was performed. In contrast, the Kruskal-Wallis test followed by the Dunn test was used for samples with a non-normal distribution. In all cases, a P value < 0.05 was considered significant.

Results
Systemic treatment with Ac2-26 decreases loss of hippocampal neurons in the SE
Behavioural analysis showed that all rats of the SE groups, treated or not with Ac2-26 peptide, displayed seizures with Racine’s score 3 to 5 and were characterised as generalised SE (Table 1). Animals from Naive and Sham groups did not show any type of seizure. During and after SE, rats’ survival rate was 100% and, 24 h after pilocarpine application, locomotion and rats’ self-feeding was normal. After DZP administration, no seizures were detected in the rats from SE groups.

In addition, neurodegenerative alterations in the hippocampus were characterised using FJC staining. At
24 h post-SE, significant neuronal injuries of pyramidal cells in anterior CA1, CA3 and posterior (dorsal and ventral) CA1 regions were evident (Fig. 1a, c, e). The systemic treatment with Ac2-26 was associated with very few degenerating neurons and no FJC + cells were detected in the control groups (Naive and Sham) (Fig. 1a, c, e). H&E stained sections of the CA regions confirmed these findings, showing neurons with pyknotic nuclei in the SE group, while SE+Ac2-26 and control groups presented a predominance of cells with a normal aspect, euchromatic nucleus and evident nucleolus (Fig. 1b, d, f).

The quantification of degenerated neurons (FJC + cells) and healthy neurons (H&E stain) were then performed in the right and left hippocampus to verify whether cannula implantation (right side) per se alters cell counting. As expected, SE produced a marked increase in the number of FJC + cells in the anterior regions of CA1, CA3 and posterior regions of CA1 compared to the Naive and Sham groups (Fig. 2a, c, e). Also, pharmacological treatment with Ac2-26 resulted in a diminished number of FJC + cells in the anterior CA1, CA3 and posterior CA1 regions in relation to the untreated SE group and presented no significant differences between control groups. These findings were corroborated by the higher number of healthy cells in the SE+Ac2-26 group compared to the untreated SE group (Fig. 2b, d, f), and the analysis of CA4/dentate gyrus regions showed similar aspects in the neurodegenerative alterations between SE and SE + Ac2-26 groups (data not shown).

Ac2-26 does not reduce the hippocampal gliosis induced by SE

The microglia population of the control groups presented a fully ramified form that characterises resting cells (Fig. 3a) [30]. At 24 h post-SE with or without Ac2-26 treatment, microglia activation in the hippocampus was evidenced by the presence of bushy and ameboid cells with few and short cytoplasmic prolongations (Fig. 3a).

The results show that the number of microglia cells (Iba-1 + cells) increased in the anterior and posterior regions of CA1 and CA3 of SE and SE+Ac2-26 groups compared to that of the controls (Naive and SHAM; Fig. 3b). Additionally, microglia counts were similar in the right and left hippocampi. Despite a marked increase in the microglia number, no differences in the ionised calcium binding adaptor molecule 1 (Iba-1) levels of the hippocampal homogenates were demonstrated among the experimental groups (Fig. 3c).

Furthermore, the results show profuse reactive astrogliosis in the anterior and posterior CA1 and CA3 regions, with increased GFAP levels being detected in the SE group compared to the controls (Fig. 4a–c). Despite similar findings regarding the quantifications of GFAP + cells between SE and SE + Ac2-26 groups, the latter showed decreased levels of hippocampal GFAP (Fig. 4a–c). Also, cannula implantation per se did not create any difference between right and left sides of the hippocampus in relation to the cell counts of all experimental groups.
The analysis of the cytokines and chemokines revealed that SE increased levels of IL-1β, IL-6, TNF-α, GRO/KC and MCP-1 in the hippocampal homogenates in relation to the control groups, indicating local inflammatory response (Fig. 5a–e). In contrast, systemic treatment with Ac2-26 reduced IL-1β, IL-6 and GRO/KC levels in relation to untreated SE and presented a similar production of TNF-α of control groups (Fig. 5a–d). However, administration of Ac2-26 maintained high levels of hippocampal MCP-1, as detected for the untreated SE group (Fig. 5e).

In addition, immunoblot analysis showed increased levels of albumin in the right and left hippocampus of SE group compared to the SE+Ac2-26, suggesting a protective effect of peptide in the disruption of BBB (Fig. 5f).

**Ac2-26 decreased Fpr2 levels in hippocampal neurons and ERK activation**

The hippocampal neurons from the SE group exhibited intense immunostaining for Fpr2 in comparison to the control and SE+Ac2-26 groups (Fig. 6a). The densitometric analysis then confirmed the immunohistochemistry findings, showing a marked increase of Fpr2 in the SE condition, which this effect was decreased by the systemic treatment with Ac2-26 (Fig. 6c). However, no differences in the Fpr2 levels were detected in the hippocampal homogenates from the SE and SE+Ac2-26 groups (Fig. 6d).
In addition, strong immunoreactivity for phosphorylated ERK (pERK) was exhibited in the hippocampal neurons from the SE group in relation to the other groups (Fig. 6b). Also, no immunostaining was detected in the sample used as negative control (Fig. 6e). Lastly, the immunoblot analysis of hippocampal homogenates showed that systemic treatment with Ac2-26 decreased levels of the pERK in relation to the untreated SE group, confirming histological findings (Fig. 6f).

**Discussion**

This study evaluated the effect of pharmacological treatment with anti-inflammatory ANXA1-derived peptide in a pilocarpine-induced SE model in rats. Using histological, histochemical, biochemical and molecular analyses, the results showed that systemic treatment with Ac2-26 decreased neuronal injury and inflammation related to SE.

As expected, at 24 h post-SE, rats that presented generalised convulsive SE (Racine’s score 3 to 5) showed the loss of bilateral hippocampal neurons, which was confirmed by reduced healthy neuron counting. Also, the bilateral lesion observed in the SE group corroborates previous data in which neurodegeneration and glial alterations occurred only ipsilaterally to the injection of pilocarpine in a generalised way since the neuronal circuitry interconnects several regions of the brain [24, 31]. Interestingly, systemic treatment of rats with Ac2-26 produced a neuroprotective effect in the areas of anterior and posterior (dorsal and ventral) CA1 and anterior CA3. These hippocampal regions are the main areas affected with neuronal loss that present the classic pattern of hippocampal sclerosis in patients with TLE [32–34], suggesting an important effect of the ANXA1-derived peptide in the SE model.

In addition to the neuronal loss, pilocarpine-induced SE produced a marked increase in the microglia and astrocyte counts in all analysed areas of the hippocampus, and this effect was not reversed by Ac2-26 treatment. These findings were corroborated by increased hippocampal levels of MCP-1 in the SE and SE+Ac2-26 groups. Then, MCP-1 released by astrocytes and endothelial cells participates in the recruitment of activated monocytes and lymphocytes in the central nervous system, acting as an important mediator in brain inflammation [35, 36]. Gliaosis is a common feature of the brains
of patients and animal models of seizures and epilepsy, and if this condition is not resolved in the post-acute or pre-chronic period, it has an inhibitory effect on nervous tissue regeneration after injury [37–39]. In this regard, hippocampal microglia from the SE and SE+Ac2-26 groups showed bushy and ameboid aspects with few and short cytoplasmic prolongations, suggesting its activation state [39]. Studies have shown that microglia releases ANXA1, in contrast to the astrocytes [16]. Additionally, Ac2-26 can induce the activation and migration of microglia to solve the inflammation [40]. Furthermore, systemic pilocarpine-induced SE in rats increased ANXA1 levels in the brain in the acute phase (24 h), gradually decreasing in the latency period (72 h to 2 weeks) and then increasing in the chronic phase (30 days), suggesting a regulatory role of ANXA1 in epilepsy [41]. Together, these data indicate that the high levels of MCP-1 in the SE model cause microglia recruitment to the hippocampus, contributing to the release of ANXA1 and consequent regulation of epileptogenesis.

Despite the detection of astrogliosis in the SE and SE+Ac2-26 groups, levels of hippocampal GFAP were reduced after treating with Ac2-26. The discrepancy in the results can be explained by the methods of analysis adopted, especially for quantifying the cells, in which only the cell bodies were considered, decreasing the profusion of cytoplasmic prolongations, which this effect was more evident in the SE group. In fact, astrocytes in the inflamed brain undergo hypertrophy of cellular processes, attenuating their stellate morphology, and is associated with GFAP upregulation and the reactive state [42, 43]. Although reactive astrocytes can be beneficial in acute injuries and chronic neurological diseases through formation of scar that encapsulates injury, seals damaged BBB and provides trophic support to regenerating axons, other forms of astrocyte reactivity appear to be harmful [43, 44]. Some studies indicated astrocytes have an important role in the generation and spread of seizure activity [42, 43]. For example, a recent study showed that astrocyte-derived amyloid-β (Aβ) peptides can mediate the degeneration of neurons through the activation of glutamatergic N-methyl-D-aspartate (NMDA) receptors in a model of TLE triggered by systemic administration of kainic acid [46]. In vitro, kainic acid reduces neuronal viability more...
Fig. 5 Effect of Ac2-26 on the cytokine and chemokine levels in the hippocampus. 

(a) IL-1β. (b) IL-6. (c) TNF-α. (d) GRO/KC. (e) MCP-1. Data represent the mean ± SEM of cytokine/chemokine dosage (pg/mL) (n = 5 animals/group). 

# P < 0.05, ## P < 0.01 and ### P < 0.001 versus Naive; * P < 0.05, ** P < 0.01 and *** P < 0.001 vs. Sham; + P < 0.05 vs. SE (Kruskal-Wallis, Dunn post-test).

Context: This figure illustrates the impact of Ac2-26 on cytokine and chemokine levels in the hippocampus. The data show significant decreases in IL-1β, IL-6, TNF-α, GRO/KC, and MCP-1 levels compared to the control groups, indicating potential anti-inflammatory effects of Ac2-26.

Fig. 6 Ac2-26 decreased Fpr2 and ERK levels in hippocampal neurons.

(a), (b) SE group showed hippocampal neurons with intense immunostain for Fpr2 and phosphorylated ERK (arrows) compared to the SHAM and SE+Ac2-26 groups. No immunostaining was detected in the sample used as a negative control. Counterstain, haematoxylin. Bars, 20 μm.

c) Fpr2 densitometric analysis of Fpr2 expression in the hippocampal neurons showed increased levels of this receptor, abrogated by Ac2-26 treatment. Data represent mean ± SEM of Fpr2 expression (a.u.; n = 5 animals/group).

## P < 0.01, ## P < 0.001 vs. Naive; *** P < 0.001 vs. Sham; ### P < 0.001 vs. SE (Kruskal-Wallis, Dunn post-test).

d, e) Immunoassays for Fpr2 (~ 40 kDa) and pERK (~ 42–44 kDa) detection in the pooled extracts of rat hippocampus (n = 3 animals/group) from all experimental groups. GAPDH and total ERK were used as protein loading controls. Immunoreactive bands for proteins were semi-quantified by densitometry and are expressed as arbitrary units (a.u.) of the ratio of Fpr2/GAPDH or pERK/ERK (data represent one illustrative blot from four independent experiments). 

Context: This figure highlights the reduction in Fpr2 and phosphorylated ERK levels in the hippocampal neurons following Ac2-26 treatment, indicating a potential role in the inhibition of neuroinflammatory processes.
in neuronal/astrocyte co-cultures than in pure neuronal culture, and this effect attenuated by precluding Aβ production [46]. Considering upregulation of GFAP is a classical hallmark of reactive astrogliosis, AC2-26 may be involved in the regulation of SE-induced reactive astrocytes and neuronal degeneration in response to pilocarpine-induced SE in the rat hippocampus.

Consistent with these findings, AC2-26 treatment also produced decreased levels of albumin in the rat hippocampus in relation to the untreated SE group, confirming the protective role of ANXA1 in the integrity of BBB multiplicity in relation to the untreated SE group, and this effect was reverted by the cant increase in the Fpr2 levels in the neurons in relation to the controls, and this effect can be explained by the fact that the hippocampus presents other cell types that also express Fpr2, especially astrocytes and microglia [58].

The binding of specific agonists to Fprs triggers several intracellular signalling cascades, including the MAPK pathway, which have key roles in several biological functions, such as angiogenesis, cell proliferation and protection against cell death [55]. Then, ERK levels were investigated to better understand the molecular mechanisms involved in the ANXA1-derived peptide in the SE model. The results indicate that SE is associated with increased ERK levels in the hippocampal neurons while administration of AC2-26 reduced ERK phosphorylation. ERK activation in epilepsy stimulates the expression of NMDA receptors, causing synaptic excitability and, in turn, leading to seizures [59].

Conclusions

Altogether, the data support that ANXA1-derived peptide attenuates the increase of astrocyte activity and release of pro-inflammatory cytokines and mitigates the severity of brain damage in the SE model by regulating Fpr2/ERK signalling pathways. These results may be of significance for the explanation of epileptogenesis and provide valuable information about the ANXA1-Fpr2 system as an important therapeutic target for TLE.

Abbreviations

AC2-26: ANXA1 N-terminal-derived peptide; ANXA1: Annexin A1; BBB: Blood-brain barrier; CA: Cornu Ammonis; DAB: 3,3’-Diaminobenzidine; D2P: Diazepam; ERK: Extracellular signal-regulated kinase; FJC: Fluoro-Jade C; Fpr2: Formyl peptide receptor 2; GADPH: Glyceraldehyde 3-phosphate dehydrogenase; GFAP: Glial fibrillary acidic protein; GRO/KC: growth-regulated alpha protein; H&E: Haematoxylin-eosin stain; Iba-1: Ionised calcium binding adaptor molecule 1; IL-1β: Interleukin-1β; IL-6: Interleukin-6; MCP-1: Monocyte chemoattractant protein-1; NMDA: Glutamatic N-methyl-D-aspartate; pERK: Phosphorylated extracellular signal-regulated kinase; SE: Status epilepticus; TLE: Temporal lobe epilepsy; TNF-α: Tumour necrosis factor-α

Acknowledgments

The authors thank Fundação de Amparo à Pesquisa do Estado de São Paulo - FAPESP and Conselho Nacional de Desenvolvimento Científico e Tecnológico - CNPq, Brazil.
Funding
This work was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo - FAPESP (Grant 2017/26872-5 to CDG and 2016/02012-4 to SMO) and Conselho Nacional de Desenvolvimento Científico e Tecnológico - CNPq (Grant 308144/2014-7 to SMO), Brazil. ADG was supported by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – CAPES (Finance Code 001).

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Authors’ contributions
ADG, OYGA and CDG conceived and designed the study and wrote the manuscript. ADG, BFA, JPP, OYGA and CDG performed the experiments and sample collection. ADG, SMO, OYGA and CDG contributed to the data analysis/interpretation. All authors have reviewed and approved the final version of the manuscript.

Ethics approval and consent to participate
All procedures were approved by the Ethics Committee in Animal Experimentation of the Federal University of São Paulo - UNIFESP (CEUA n° 295,805,081) and agreed with the guidelines established by the National Council for the Control of Animal Experimentation (ConceEA).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Morphology and Genetics, Federal University of São Paulo (UNIFESP), São Paulo, SP 04023-900, Brazil. 2Department of Molecular Biology, São José do Rio Preto School of Medicine (FAMERP), São José do Rio Preto, SP 15090-000, Brazil. 3From the Post-Graduation in Biosciences, Instituto de BiocIÊncias, Letras e Ciências Exatas, São Paulo State University (IBILCE/UNESP), São José do Rio Preto, SP 15054-000, Brazil.

Received: 6 November 2018 Accepted: 24 January 2019

Published online: 12 February 2019

References
1. Fisher RS, van Emde BW, Blume W, Elger C, Genton P, Lee P, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 2005;46(4):470–2.
2. Mathern GW, Adelson PD, Cahon LD, Leite JP. Hippocampal neuron damage in human epilepsy: Meyer’s hypothesis revisited. Prog Brain Res. 2002;135:237–51.
3. Curia G, Longo D, Biagioni G, Jones RS, Avoli M. The pilocarpine model of temporal lobe epilepsy. J Neurosci Methods. 2008;172(2):143–57.
4. Leite JP, Bortolotto ZA, Cavalheiro EA. Spontaneous recurrent seizures in rats: an experimental model of partial epilepsy. Neurosci Biobehav Rev. 1990;14(4):511–7.
5. Cavalheiro EA, Leite JP, Bortolotto ZA, Turski WA, Ikonomidou C, Turski L. Long-term effects of pilocarpine in rats: structural damage of the brain triggers kindling and spontaneous recurrent seizures. Epilepsia. 1991;32(6):778–82.
6. Wieser HG. Epilepsy. Kno. ILAE Commission Report. Mesial temporal lobe epilepsy with hippocampal sclerosis. Epilepsia. 2004;45(5):695–714.
7. Kandratavicius L, Balista PA, Lopes-Aguiar C, Ruggiero RN, Umeoka EH, Garcia-Cairasco N, et al. Animal models of epilepsy: use and limitations. Neuropsychiatr Dis Treat. 2014;10:1693–705.
8. Curia G, Lucchi C, Vinet J, Guattieri F, Marinelli C, Torsello A, et al. Pathophysiology of mesial temporal lobe epilepsy is prevention of damage against epileptogenesis? Curr Med Chem. 2014;21(6):683–88.
9. Guattieri F, Curia G, Marinelli C, Biagioni G. Increased perivascular lamrin predicts damage to astrocytes in CA3 and piriform cortex following chemoconvulsant treatments. Neuroscience. 2012;218:278–94.

10. Vezzani A, Friedman A, Dingledine R. The role of inflammation in epileptogenesis. Neuropharmacology. 2013;69:16–24.
11. Terrone G, Salamone A, Vezzani A. Inflammation and epilepsy: preclinical findings and potential clinical translation. Curr Pharm Des. 2012;18(37):5569–76.
12. Vezzani A, Bartfi T, Bianchi M, Rossetti C, French J. Therapeutic potential of new antiinflammatory drugs. Epilepsia. 2011;52(suppl 8):667–9.
13. Uldag IF, Duktsal T, Tiftikcioglu B, Zorlu Y, Ozkaya F, Kirkali G. IL-1β, IL-6 and IL-1Ra levels in temporal lobe epilepsy. Seizure. 2015;26:22–5.
14. Sheikh MH, Solto E. Annexin A1: uncovering the many talents of an old protein. Int J Mol Sci. 2018;19(4):E1045.
15. Solto E, McArthur S, Christian H, Gavins F, Buckingham JC, Gilles GE. Annexin A1 in the brain – undiscovered roles? Trends Pharmacol Sci. 2008;29(3):33–42.
16. Young KA, Hirst WD, Solto E, Wilkin GP. De novo expression of lipocortin-1 in reactive microglia and astrocytes in kainic acid lesioned rat cerebellum. Glia. 1999;26(4):333–43.
17. Gavins FN, Dalli J, Flower RJ, Granger DN, Perretti M. Activation of the annexin 1 counter-regulatory circuit affords protection in the mouse brain microcirculation. FASEB J. 2007;21(8):2751–8.
18. Smith HK, Gil CD, Oliani SM, Gavins FN. Targeting formyl peptide receptor 2 reduces leukocyte-endothelial interactions in a murine model of stroke. FASEB J. 2015;29(5):2016–71.
19. Ries M, Liolia R, Shah UN, Gentleman SM, Solto E, Sastre M. The anti-inflammatory annexin A1 induces the clearance and degradation of the amyloid-β peptide. J Neuroinflammation. 2016;13(1):234.
20. Walther A, Rehemann K, Gerke V. A novel ligand of the formyl peptide receptor: annexin 1 regulates neutrophil extravasation by interacting with the FPR. Mol Cell. 2000;5(5):831–40.
21. Perucci LQ, Sugimoto MA, Gomes KB, Dusse LM, Teixeira MM, Sousa LP. Annexin A1 and specialized proresolving lipid mediators: promoting resolution as a therapeutic strategy in human inflammatory diseases. Expert Opin Ther Targets. 2017;21(9):879–96.
22. Pernice H, Schweick R, Kiebler MA, Popper B, mTOR and MAPK from localized translation control to epilepsy. BMC Neurosci. 2016;17(1):73.
23. Castro OW, Furtado MA, Tiliel CQ, Fernandes A, Pajolla GP, Garcia-Cairasco N. Comparative neuroanatomical and temporal characterization of fluoroJade-positive neurodegeneration after status epilepticus induced by systemic and intrahippocampal pilocarpine in Wistar rats. Brain Res. 2011;1374:45–55.
24. Furtado MA, Castro OW, Del Vecchio F, de Oliveira JA, Garcia-Cairasco N. Study of spontaneous recurrent seizures and morphological alterations after status epilepticus induced by intrahippocampal injection of pilocarpine. Epilepsy Behav. 2011;20(2):257–66.
25. Girol AP, Mimura K, Drewees CC, Boonheis SM, Gavins FN. Anti-inflammatory mechanisms of the annexin A1 protein and its mimetic peptide Ac2–26 in models of ocular inflammation in vivo and in vitro. J Immunol. 2013;190(11):5689–701.
26. Gimenes AD, Andrade TR, Mello CB, Ramos L, Gil CD, Oliani SM. Beneficial effect of annexin A1 in a model of experimental allergic conjunctivitis. Exp Eye Res. 2015;134:24–32.
27. Racine RJ. Modification of seizure activity by electrical stimulation. II Motor seizure Electroencephalogr Clin Neurophysiol. 1972;32(3):281–94.
28. Schmued LC, Albertson C, Slikker W. Fluoro-jade: a novel fluorochrome for the sensitive and reliable histochemical localization of neuronal degeneration. Brain Res. 1997;751(1):37–46.
29. Abercrombie M. Estimation of nuclear population from microtome sections. Anat Rec. 1946;94:239–47.
30. Karpenen A, Ahammer H, Jelink HF. Quantitating the subtleties of microglial morphology with fractal analysis. Front Cell Neurosci. 2013;7:3.
31. Furtado MA, Braga GK, Oliveira JA, Del Vecchio F, Garcia-Cairasco N. Behavioral, morphologic, and electroencephalographic evaluation of seizures induced by intrahippocampal microinjection of pilocarpine. Epilepsia. 2002;43(suppl 5):37–9.
32. Thom M, Lagkouras I, Elliot KJ, Martinian L, Hankins W, McEvoy A, et al. Reliability of patterns of hippocampal sclerosis as predictors of postsurgical outcome. Epilepsia. 2010;51(1):1981–8.
33. Malmgren K, Thom M. Hippocampal sclerosis—origins and imaging. Epilepsia. 2012;53(suppl 4):19–33.
34. Steve TA, Jirisch JD, Gross DW. Quantification of subfield pathology in hippocampal sclerosis: a systematic review and meta-analysis. Epilepsy Res. 2014;108(8):1279–85.
35. Yadav A, Saini V, Arora S. MCP-1: chemoattractant with a role beyond immunity: a review. Clin Chim Acta. 2010;411(21–22):1570–9.
36. Sawyer AJ, Tian W, Saucier-Sawyer JK, Rizk PJ, Saltzman WM, Bellamkonda RV, et al. The effect of inflammatory cell-derived MCP-1 loss on neuronal survival during chronic neuroinflammation. Biomaterials. 2014;35(25):6989–706.
37. Borges K, Gearing M, McDermott DL, Smith AB, Almonte AG, Wainer BH, et al. Neuronal and glial pathological changes during epileptogenesis in the mouse pilocarpine model. Exp Neurol. 2003;182(1):21–34.
38. Loewen JL, Barker-Haliski ML, Dahle EJ, White HS, Wilcox KS. Neuronal injury, gliosis, and glial proliferation in two models of temporal lobe epilepsy. J Neuropathol Exp Neurol. 2016;75(4):366–78.
39. Johnson AM, Sugo E, Barreto D, Hiew CC, Lawson JA, Connolly AM, et al. The severity of gliosis in hippocampal sclerosis correlates with pre-operative seizure burden and outcome after temporal lobectomy. Mol Neurobiol. 2016;53(8):546–56.
40. Liu S, Gao Y, Yu X, Zhao B, Liu L, Zhao Y, et al. Annexin-1 mediates microglial activation and migration via the CK2 Pathway during oxygen-glucose deprivation/reperfusion. Int J Mol Sci. 2016;17(10):1770.
41. Yao BZ, Yu SQ, Yuan H, Zhang HJ, Niu P, Ye JP. The role and effects of ANXA1 in temporal lobe epilepsy: a protection mechanism? Med Sci Monit Basic Res. 2015;21:241–6.
42. Wetherington J, Serrano G, Dingledine R. Astrocytes in the epileptic brain. Neuron. 2008;58(2):168–78.
43. Liddelow SA, Barres BA. Reactive astrocytes: production, function, and therapeutic potential. Immunity. 2017;46(6):957–67.
44. Vargas-Sánchez K, Mogilevskaya M, Rodríguez-Pérez J, Javela JJ, González-Reyes RE. Astroglial role in the pathophysiology of status. Oncotarget. 2018;9(42):26954–76.
45. Hadera MG, Elogoï H, Jaradat S, Nehlig A, Sonnewald U. Astrocyte-neuronal interactions in epileptogenesis. J Neurosci Res. 2015;93(7):1157–64.
46. Kodam A, Ourdov D, Mauilk M, Harirakhrishnan J, Banerjee M, Wang Y, et al. A role for astrocyte-derived amyloid β peptides in the degeneration of neurons in an animal model of temporal lobe epilepsy. Brain Pathol. 2018;28(1):28–44.
47. Cristante E, McArthur S, Mauro C, Maggioli E, Romero IA, Wylezsinska-Ariddle M, et al. Identification of an essential endogenous regulator of blood-brain barrier integrity, and its pathological and therapeutic implications. Proc Natl Acad Sci U S A. 2013;110(3):832–41.
48. Park JC, Bakh SH, Han SH, Cho HJ, Choi H, Kim HJ, et al. Annexin A1 restores Aβ. Aging Cell. 2017;16(1):149–61.
49. Marchi N, Granata T, Jangjo D. Inflammatory pathways of seizure disorders. Trends Neurosci. 2014;37(2):55–65.
50. Gorter JA, van Vliet EA, Aronica E. Status epilepticus, blood-brain barrier disruption, inflammation, and epileptogenesis. Epilepsy Behav. 2015;49:13–6.
51. de Vries EE, van den Munchhof B, Braun KP, van Ruyen-Kerkhoff A, de Jager W, Jansen FE. Inflammatory mediators in human epilepsy: a systematic review and meta-analysis. Neuosci Biobehav Rev. 2016;63:177–90.
52. Fredman G, Kamaly N, Spolitus S, Milton J, Ghorpade D, Chiaisson R, et al. Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice. Sci Transl Med. 2015;7(275):275ra20.
53. Scorza CA, Marques MJG, Gomes da Silva S, MDG N-M, Scorza FA, Carvalheiro EA. Status epilepticus does not induce acute brain inflammatory response in the Amazon rodent Proechimys, an animal model resistant to epileptogenesis. Neurosci Lett. 2018;668:169–73.
54. Gavins FN, Hughes EL, Buss NA, Holloway PM, Getting SJ, Buckingham JC. Leukocyte recruitment in the brain in sepsis: involvement of the annexin 1-FPR2/ALX anti-inflammatory system. FASEB J. 2012;26(12):4977–89.
55. Cattaneo F, Guerra G, Ammendola R. Expression and signaling of formyl-peptide receptors in the brain. Neurochem Res. 2010;35(12):2018–26.
56. He N, Jin WL, Lok KH, Wang Y, Yin M, Wang ZJ. Amyloid-(1-42) oligomer accelerates senescence in adult hippocampal neural stem/progenitor cells via formylpeptide receptor 2. Cell Death Dis. 2013;4:e924.
57. Zhang L, Wang G, Chen X, Xue X, Guo Q, Liu M, et al. Formyl peptide receptors promotes neural differentiation in adult hippocampal neural stem/progenitor cells via formylpeptide receptor 2. Cell Death Dis. 2013;4:e924.
58. Braun BJ, Slocki A, Leib SL, Lucius R, Varoga D, Wruck CJ, et al. The formyl-peptide receptor like-1 and scavenger receptor MARCO are involved in glial cell activation in bacterial meningitis. J Neuroinflammation. 2011;8(1):11.
59. Nateri AS, Ravich G, Gebhardt C, Da Costa C, Naumann H, Vreugdenhil M, et al. ERK activation causes epilepsy by stimulating NMDA receptor activity. EMBO J. 2007;26(23):4891–901.